FrancophonIA/ELRC3.0 huggingface dataset:
English: Uncommon: Bullous eruption, seborrhoea, rosacea, skin papilloma, hyperkeratosis, abnormal skin pigmentation.
Croatian: Često: hipotenzija, hipertenzija, ekhimoza, navala vrućine, navale crvenila Manje često: periferna ishemija, tromboflebitis, hematom Rijetko: zatajenje cirkulacije, petehije, vazospazam
English: Ulcerative colitis Paediatric Ulcerative colitis
Croatian: Paediatric Ulcerative Colitis Activity Index, PUCAI).
English: Percentage of subjects with mucosal healing Mucosal healing at week 8
Croatian: Postotak ispitanika s cijeljenjem sluznice Cijeljenje sluznice u 8. tjednu
English: • Nettle-type rash (hives), itchy rash or dry skin
Croatian: • koprivnjača (osip), osip praćen svrbežom ili suha koža
English: Common: Gastrointestinal haemorrhage, diarrhoea, dyspepsia, gastroesophageal reflux, constipation.
Croatian: Poremećaji probavnog sustava Vrlo često: bol u abdomenu, mučnina Često: gastrointestinalno krvarenje, proljev, dispepsija, gastroezofagealni refluks, konstipacija Manje često: perforacija crijeva, stenoza crijeva, divertikulitis, pankreatitis, heilitis
English: Rare: Toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, furunculosis, linear IgA bullous dermatosis (LABD), acute generalised exanthematous pustulosis (AGEP), lichenoid reactions.
Croatian: Često: novonastala psorijaza ili pogoršanje postojeće uključujući pustularnu psorijazu (primarno palmarnu i plantarnu), urtikarija, osip, svrbež, hiperhidroza, suha koža, gljivični dermatitis, ekcem, alopecija Manje često: bulozne erupcije, seboreja, rozacea, papilomi, hiperkeratoza, poremećaj pigmentacije Rijetko: toksična epidermalna nekroliza, Stevens-Johnsonov sindrom, multiformni eritem, furunkuloza, linearna IgA bulozna dermatoza (LABD), akutna generalizirana egzantematozna pustuloza (AGEP), lihenoidne reakcije Nepoznato: pogoršanje simptoma dermatomiozitisa
English: 3 mg/kg q 8 wks
Croatian: 3 mg/kg svakih 8 tjedana
English: Rare: Interstitial lung disease (including rapidly progressive disease, lung fibrosis and pneumonitis).
Croatian: Vrlo često: infekcija gornjih dišnih puteva, sinusitis Često: infekcija donjih dišnih puteva (npr. bronhitis, pneumonija), dispneja, epistaksa Manje često: edem pluća, bronhospazam, pleuritis, pleuralni izljev Rijetko: intersticijska bolest pluća (uključujući brzu progresivnu bolest, fibrozu pluća i pneumonitis)
English: The Health Assessment Questionnaire (HAQ; scale 0-3) was used to measure patients' average change from baseline scores over time, in physical function.
Croatian: Health Assessment Questionnaire, HAQ; skala 0-3).
English: There have been reports of active tuberculosis in patients receiving Remicade.
Croatian: U bolesnika liječenih lijekom Remicade prijavljeni su slučajevi aktivne tuberkuloze.
English: Some of these infections have been fatal; the most frequently reported opportunistic infections with a mortality rate of > 5% include pneumocystosis, candidiasis, listeriosis and aspergillosis.
Croatian: > 5% uključuju pneumocistozu, kandidijazu, listeriozu i aspergilozu.
English: Table 1 Undesirable effects in clinical studies and from post-marketing experience Infections and infestations Very Common: Viral infection (e.g. influenza, herpes virus infection).
Croatian: Tablica 1 Nuspojave u kliničkim ispitivanjima i nakon stavljanja lijeka u promet Infekcije i infestacije
English: Chronic Obstructive Pulmonary Disease (COPD) or if you are a heavy smoker.
Croatian: • Prije nego počnete primati Remicade, obavijestite svog liječnika ako bolujete od bolesti pluća koja se zove kronična opstruktivna plućna bolest (KOPB) ili ste teški pušač.
English: Adult rheumatoid arthritis
Croatian: Reumatoidni artritis u odraslih bolesnika
English: Tell your doctor straight away if you get signs of TB during treatment with Remicade.
Croatian: Odmah obavijestite svog liječnika ako tijekom liječenja lijekom Remicade dobijete simptome tuberkuloze.
English: 3 mg/kg q 4 wks
Croatian: 3 mg/kg svaka 4 tjedna
English: Caution should be exercised in considering treatment of patients with increased risk for malignancy due to heavy smoking.
Croatian: U bolesnika koji imaju povećan rizik za razvoj maligne bolesti jer su teški pušači mogućnost liječenja lijekom Remicade treba razmotriti uz oprez.
English: 10 mg/kg q 4 wks
Croatian: 10 mg/kg svaka 4 tjedna ukupno infliksimab
English: Uncommon: Cardiac failure (new onset or worsening), arrhythmia, syncope, bradycardia.
Croatian: Često: tahikardija, palpitacije Manje često: zatajenje srca (novonastalo ili pogoršanje postojećeg), aritmija, sinkopa, bradikardija Rijetko: cijanoza, perikardijalni izljev Nepoznato: ishemija miokarda/infarkt miokarda Krvožilni poremećaji
English: For patients who have resided in or travelled to regions where invasive fungal infections such as histoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of Remicade treatment should be carefully considered before initiation of Remicade therapy.
Croatian: Prije uvođenja lijeka Remicade treba pažljivo ocijeniti koristi i rizike liječenja ovim lijekom u bolesnika koji su boravili ili putovali u područja za koja su karakteristične endemske invazivne gljivične infekcije kao što su histoplazmoza, kokcidioidomikoza ili blastomikoza.
English: CARTON
Croatian: Cijepljenje
English: The company will also prepare a similar pack for patients.
Croatian: Tvrtka će sličan paket pripremiti i za bolesnike.
English: When the body cannot remove iron effectively, the excess iron can cause damage.
Croatian: Kada tijelo ne može učinkovito ukloniti željezo, višak željeza može uzrokovati oštećenja.
English: Further information on Deferasirox Mylan can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/deferasirox-mylan.
Croatian: Više informacija o lijeku Deferasirox Mylan dostupno je na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/deferasirox-mylan.
English: The dose is then adjusted as needed, every 3 to 6 months, according to the iron levels in the blood.
Croatian: Doza se prilagođava svaka tri mjeseca do šest mjeseci prema potrebi, ovisno o razinama željeza u krvi.
English: Deferasirox Mylan is available as film-coated tablets (90 mg, 180 mg and 360 mg), to be taken once a day at around the same time.
Croatian: Lijek Deferasirox Mylan dostupan je u obliku filmom obloženih tableta (90 mg, 180 mg i 360 mg) koje se uzimaju jedanput dnevno otprilike u isto vrijeme.
English: This helps to correct the iron overload and prevent damage to organs such as the heart or liver from excess iron.
Croatian: To pomaže u ispravljanju preopterećenja željezom i sprečavanju oštećenja organa, primjerice srca ili jetre, zbog viška željeza.
English: It attaches to excess iron in the body to form a compound called a ‘chelate' that can be removed by the body, mainly in the stool.
Croatian: Veže se na višak željeza u tijelu i stvara spoj koji se naziva „kelat” i koji se može ukloniti iz tijela, uglavnom kroz stolicu.
English: Non-transfusion-dependent thalassaemia syndromes are blood disorders similar to beta thalassaemia major but which do not require blood transfusions.
Croatian: Sindromi talasemije neovisni o transfuziji poremećaji su krvi slični beta-talasemiji major, ali koji ne zahtijevaju transfuziju krvi.
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Exjade, and do not need to be repeated for Deferasirox Mylan.
Croatian: Ispitivanja koristi i rizika od djelatne tvari u odobrenim primjenama već su provedena s referentnim lijekom Exjade i stoga ih nije potrebno ponavljati za Deferasirox Mylan.
English: This means that Deferasirox Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Exjade.
Croatian: To znači da Deferasirox Mylan sadrži istu djelatnu tvar i djeluje na jednak način kao i „referentni lijek” koji je već odobren u EU-u pod nazivom Exjade.
English: Because Deferasirox Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Deferasirox Mylan generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Deferasirox Mylan have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Deferasirox Mylan nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Deferasirox Mylan is a medicine used to treat chronic iron overload (an excess of iron in the body) in:
Croatian: Deferasirox Mylan je lijek koji se koristi za liječenje kroničnog preopterećenja željezom (prevelike količine željeza u tijelu) u:
English: This pack aims to inform them about the treatment recommendations with Deferasirox Mylan, including choosing the right dose and the need to monitor the patient's health, especially kidney function.
Croatian: Svrha tog paketa jest obavijestiti zdravstvene djelatnike o preporukama za liječenje lijekom Deferasirox Mylan, uključujući odabir prave doze i o tome da je potrebno nadzirati bolesnikovo zdravstveno stanje, osobito funkciju rada bubrega.
English: What measures are being taken to ensure the safe and effective use of Deferasirox Mylan?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Deferasirox Mylan?
English: The company that markets Deferasirox Mylan must issue an education pack to healthcare professionals.
Croatian: Tvrtka koja stavlja lijek Deferasirox Mylan u promet mora objaviti edukacijski paket za zdravstvene radnike.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Deferasirox Mylan has been shown to have comparable quality and to be bioequivalent to Exjade.
Croatian: Europska agencija za lijekove zaključila je kako je, u skladu sa zahtjevima EU-a, utvrđeno da lijek Deferasirox Mylan ima usporedivu kakvoću te da je bioekvivalentan s lijekom Exjade.
English: In these patients iron overload is caused by excess absorption of iron from the gut.
Croatian: U takvih je bolesnika preopterećenje željezom uzrokovano prekomjernom apsorpcijom željeza iz crijeva.
English: Side effects reported with Deferasirox Mylan are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Deferasirox Mylan pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Deferasirox Mylan (deferasirox)
Croatian: Deferasirox Mylan (deferasiroks)
English: Deferasirox Mylan can only be obtained with a prescription and treatment should be started and supervised by a doctor who is experienced in the treatment of chronic iron overload.
Croatian: Deferasirox Mylan izdaje se samo na recept, a liječenje mora započeti i nadzirati liječnik s iskustvom u liječenju kroničnog preopterećenja željezom.
English: Therefore, the Agency's view was that, as for Exjade, the benefits of Deferasirox Mylan outweigh the identified risks and it can be authorised for use in the EU.
Croatian: Stoga je stav Agencije da, kao i kod lijeka Exjade, koristi od lijeka Deferasirox Mylan nadmašuju identificirane rizike te da lijek može biti odobren za primjenu u EU-u.
English: An overview of Deferasirox Mylan and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Deferasirox Mylan i zašto je odobren u EU-u
English: As for every medicine, the company provided studies on the quality of Deferasirox Mylan.
Croatian: Kao i za svaki lijek, tvrtka je dostavila podatke o ispitivanjima kakvoće lijeka Deferasirox Mylan.
English: For more information about using Deferasirox Mylan, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Deferasirox Mylan pročitajte uputu o lijeku odnosno obratite se liječniku ili ljekarniku.
English: As for all medicines, data on the use of Deferasirox Mylan are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Deferasirox Mylan kontinuirano se prate.
English: What is Deferasirox Mylan and what is it used for?
Croatian: Što je Deferasirox Mylan i za što se koristi?
English: What are the benefits and risks of Deferasirox Mylan?
Croatian: Koje su koristi i rizici od lijeka Deferasirox Mylan?
English: • patients from 6 years of age who have beta thalassaemia major (an inherited blood disorder in which patients do not have enough normal haemoglobin - the protein that carries oxygen around the body - in the blood) and who receive frequent blood transfusions;
Croatian: • bolesnika u dobi od 6 godina i starijih koji imaju beta-talasemiju major (nasljedni poremećaj krvi pri kojem bolesnici nemaju normalne vrijednosti hemoglobina u krvi, proteina koji prenosi kisik u tijelu) i koji često primaju transfuziju krvi;
English: The active substance in Deferasirox Mylan, deferasirox, is an ‘iron chelator'.
Croatian: Djelatna tvar u lijeku Deferasirox Mylan, deferasiroks, jest „kelator željeza”.
English: Other information about Deferasirox Mylan
Croatian: Ostale informacije o lijeku Deferasirox Mylan
English: The starting dose of Deferasirox Mylan depends on the patient's body weight, what the medicine is used for, and on the level of iron overload.
Croatian: Početna doza lijeka Deferasirox Mylan ovisi o tjelesnoj težini bolesnika, razlogu za liječenje i razini preopterećenja željezom.
English: Why is Deferasirox Mylan authorised in the EU?
Croatian: Zašto je lijek Deferasirox Mylan odobren u EU-u?
English: Deferasirox Mylan contains the active substance deferasirox and is a ‘generic medicine'.
Croatian: Deferasirox Mylan sadrži djelatnu tvar deferasiroks te je „generički lijek”.
English: • children aged 2 to 5 years with beta thalassaemia major who receive frequent blood transfusions, when deferoxamine (another medicine used to treat iron overload) cannot be used or is inadequate;
Croatian: • djece u dobi od 2 do 5 godina s beta-talasemijom major koja često primaju transfuziju krvi u slučaju kada se deferoksamin (drugi lijek koji se koristi za liječenje preopterećenja željezom) ne može primjenjivati ili kada njegova primjena nije prikladna;
English: • patients from 2 years of age who suffer from other types of anaemia (low levels of haemoglobin in the blood) and who receive blood transfusions, when deferoxamine cannot be used or is inadequate;
Croatian: • bolesnika u dobi od 2 godine i starijih s drugim vrstama anemije (niskim razinama hemoglobina u krvi) i koji primaju transfuziju krvi u slučaju kada se deferoksamin ne može primjenjivati ili kada njegova primjena nije prikladna;
English: • patients from 10 years of age with non-transfusion-dependent thalassaemia syndromes, when deferoxamine cannot be used or is inadequate.
Croatian: • bolesnika u dobi od 10 godina i starijih sa sindromima talasemije neovisnima o transfuziji u slučaju kada se deferoksamin ne može primjenjivati ili kada njegova primjena nije prikladna.
English: How has Deferasirox Mylan been studied?
Croatian: Kako je Deferasirox Mylan ispitivan?
English: How does Deferasirox Mylan work?
Croatian: Kako djeluje Deferasirox Mylan?
English: • patients from 2 years of age with beta thalassaemia major who receive infrequent blood transfusions, when deferoxamine cannot be used or is inadequate;
Croatian: • bolesnika u dobi od 2 godine i starijih s beta-talasemijom major i neučestalim transfuzijama krvi u slučaju kada se deferoksamin ne može primjenjivati ili kada njegova primjena nije prikladna;
English: How is Deferasirox Mylan used?
Croatian: Kako se Deferasirox Mylan primjenjuje?
English: The recommended dose is two inhalations twice a day.
Croatian: Preporučena su doza dva udisaja dvaput na dan.
English: Further information on Trydonis can be found on the Agency's website: https://www.ema.europa.eu/en/medicines/human/EPAR/trydonis.
Croatian: Više informacija o lijeku Trydonis možete pronaći na internetskim stranicama Agencije: https://www.ema.europa.eu/en/medicines/human/EPAR/trydonis.
English: Other information about Trydonis
Croatian: Ostale informacije o lijeku Trydonis
English: Trydonis received a marketing authorisation valid throughout the EU on 26 April 2018.
Croatian: Lijek Trydonis dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 26. travnja 2018.
English: The company that makes Trimbow has agreed that its scientific data can be used for Trydonis (‘informed consent').
Croatian: Tvrtka koja proizvodi lijek Trimbow pristala je da se njezini znanstveni podatci upotrijebe za lijek Trydonis („informirani pristanak”).
English: It works in a similar way to naturally occurring corticosteroid hormones, reducing the activity of the immune system.
Croatian: Djeluje na sličan način kao prirodni kortikosteroidni hormoni, odnosno smanjuje aktivnost imunosnog sustava.
English: What measures are being taken to ensure the safe and effective use of Trydonis?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Trydonis?
English: The European Medicines Agency therefore decided that Trydonis's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove stoga je zaključila da koristi od lijeka Trydonis nadmašuju s njim povezane rizike te da može biti odobren za primjenu u EU-u.
English: What is Trydonis and what is it used for?
Croatian: Što je Trydonis i za što se primjenjuje?
English: Trydonis (beclometasone / formoterol / glycopyrronium bromide)
Croatian: Trydonis (beklometazon / formoterol / glikopironijev bromid)
English: Side effects reported with Trydonis are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Trydonis pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: As for all medicines, data on the use of Trydonis is continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Trydonis kontinuirano se prate.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Trydonis have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Trydonis nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: What are the risks associated with Trydonis?
Croatian: Koji su rizici povezani s lijekom Trydonis?
English: Why is Trydonis authorised in the EU?
Croatian: Zašto je lijek Trydonis odobren u EU-u?
English: Patients should be shown how to use the inhaler correctly by a doctor or another healthcare professional, who should also regularly check that the patient's inhalation technique is correct.
Croatian: Liječnik ili neki drugi zdravstveni radnik treba pokazati bolesnicima kako se ispravno koristiti inhalatorom, a osim toga treba redovito provjeravati primjenjuje li bolesnik ispravnu tehniku inhaliranja.
English: Trydonis is available as a liquid in a portable inhaler device.
Croatian: Lijek Trydonis dostupan je kao tekućina u prijenosnom inhalatoru.
English: An overview of Trydonis and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Trydonis i zašto je odobren u EU-u
English: Beta-2 agonists and muscarinic receptor antagonists help to widen the airways; corticosteroids reduce inflammation in the airways and lungs..
Croatian: Beta-2 agonisti i antagonisti muskarinskih receptora pomažu u širenju dišnih putova, a kortikosteroidi smanjuju upalu u dišnim putovima i plućima.
English: Beclometasone belongs to anti-inflammatory medicines known as corticosteroids.
Croatian: Beklometazon pripada skupini protuupalnih lijekova koji se nazivaju kortikosteroidi.
English: In the first study lasting a year, after 26 weeks of treatment, Trydonis improved patients' FEV1 (the maximum volume of air a person can breathe out in one second) by 82 ml before a dose and 261 ml after a dose.
Croatian: U prvom ispitivanju koje je trajalo godinu dana, nakon 26 tjedana terapije lijekom Trydonis poboljšao se FEV1 (najveći volumen zraka koji osoba može izdahnuti u jednoj sekundi) bolesnika za 82 ml prije primjene jedne doze i za 261 ml nakon primjene jedne doze.
English: Side effects with Trydonis include oral candidiasis (a fungal infection of the mouth caused by a yeast called Candida), muscle spasms and dry mouth.
Croatian: U nuspojave lijeka Trydonis ubrajaju se oralna kandidijaza (gljivična infekcija usta uzrokovana gljivicom Candida), mišićni grčevi i suha usta.
English: Trydonis is a medicine used in adults to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD).
Croatian: Trydonis je lijek za odrasle osobe kojim se ublažavaju simptomi umjerene do teške kronične opstruktivne plućne bolesti (KOPB).
English: It attaches to receptors (targets) known as beta-2 receptors in the muscles of the airways.
Croatian: Spaja se na receptore (ciljna mjesta) naziva beta-2 receptori koji se nalaze u mišićima dišnih putova.
English: For more information about using Trydonis, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Trydonis pročitajte u uputi o lijeku odnosno obratite se liječniku ili ljekarniku.
English: What benefits of Trydonis have been shown in studies?
Croatian: Koje su koristi od lijeka Trydonis utvrđene u ispitivanjima?
English: Trydonis has been shown to be effective at relieving symptoms of COPD in three main studies involving over 5,500 patients whose symptoms were not controlled well enough either by combinations of two other COPD medicines or by a muscarinic receptor antagonist alone.
Croatian: Utvrđeno je da Trydonis učinkovito ublažava simptome KOPB-a u trima glavnim ispitivanjima na više od 5 500 bolesnika čiji simptomi nisu bili odgovarajuće kontrolirani ni kombinacijom drugih dvaju lijekova protiv KOPB-a ni monoterapijom antagonistom muskarinskih receptora.
English: By comparison, the FEV1 increased by 1 and 145 ml before and after dosing in patients treated with a medicine containing only 2 of the active substances found in Trydonis (beclometasone plus formoterol).
Croatian: Za usporedbu, FEV1 povećao se za 1 ml prije odnosno 145 ml nakon doziranja u bolesnika liječenih lijekom koji je sadržavao samo dvije djelatne tvari lijeka Trydonis (beklometazon i formoterol).
English: No major safety concerns have been reported with Trydonis, with side effects being manageable and similar to other COPD medicines.
Croatian: Nisu prijavljeni ozbiljniji razlozi za zabrinutost u pogledu sigurne primjene lijeka Trydonis, a nuspojave se mogu kontrolirati i slične su nuspojavama ostalih lijekova protiv KOPB-a.
English: Trydonis is used for maintenance (continuing) treatment in patients whose disease is not adequately controlled despite treatment with a combination of two COPD medicines consisting of a long-acting beta-2 agonist plus either an inhaled corticosteroid or a long-acting muscarinic receptor antagonist.
Croatian: Trydonis se upotrebljava kao kontinuirana terapija (terapija održavanja) u bolesnika čija bolest nije odgovarajuće kontrolirana unatoč liječenju kombinacijom dvaju lijekova za KOPB koja se sastoji od beta-2 agonista i inhalacijskog kortikosteroida ili dugodjelujućeg antagonista muskarinskih receptora.
English: Trydonis contains the active substances beclometasone, formoterol and glycopyrronium bromide.
Croatian: Trydonis sadržava djelatne tvari beklometazon, formoterol i glikopironijev bromid.
English: The three active substances in Trydonis work in different ways to reduce inflammation and keep the airways open, allowing the patient to breathe more easily.
Croatian: Tri djelatne tvari u lijeku Trimbow djeluju na različite načine kako bi se smanjila upala i dišni putovi držali otvorenima, čime se bolesniku omogućuje lakše disanje.